| Multiple Sclerosis |
1 |
1 |
| Biosimilars |
0 |
0.94 |
| Biologic Therapy |
0 |
0.95 |
| Disability |
0 |
0.19 |
| Crohn Disease |
0 |
0.14 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.13 |
| Brain |
0 |
0.09 |
| Clinically Isolated Syndrome (CIS) |
0 |
0.09 |
| Europe |
0 |
0.09 |
| Intravenous |
0 |
0.09 |
| JC Virus |
0 |
0.09 |
| Leukoencephalopathy |
0 |
0.09 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.09 |
| Viral Infection |
0 |
0.09 |
| Patient Safety |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |